Private equity firms own 59% of IO Biotech, with institutions holding 22%. The top 5 shareholders control 54% of the company. Insider ownership is under 1%. Public investors own 19% of the company. Private equity firms may influence key decisions.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing